| DUCHNOWSKA, Renata, Piotr J. WYSOCKI, Konstanty KORSKI, Bogumiła CZARTORYSKA-ARŁUKOWICZ, Anna NIWIŃSKA, Marlena ORLIKOWSKA, Barbara RADECKA, Maciej STUDZIŃSKI, Regina DEMLOVÁ, Barbara ZIÓŁKOWSKA, Monika MERDALSKA, Łukasz HAJAC, Paulina MYŚLIWIEC, Dorota ZUZIAK, Sylwia DĘBSKA-SZMICH, Istvan LANG, Małgorzata FOSZCZYŃSKA-KŁODA, Bożenna KARCZMAREK-BOROWSKA, Anton ŻAWROCKI, Anna KOWALCZYK, Wojciech BIERNAT a Jacek JASSEM. Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. Oncotarget. Albany: Impact Journals, 2016, roč. 7, č. 1, s. 550-564. ISSN 1949-2553. Dostupné z: https://dx.doi.org/10.18632/oncotarget.6375. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1369178,
author = {Duchnowska, Renata and Wysocki, Piotr J. and Korski, Konstanty and CzartoryskaandArłukowicz, Bogumiła and Niwińska, Anna and Orlikowska, Marlena and Radecka, Barbara and Studziński, Maciej and Demlová, Regina and Ziółkowska, Barbara and Merdalska, Monika and Hajac, Łukasz and Myśliwiec, Paulina and Zuziak, Dorota and DębskaandSzmich, Sylwia and Lang, Istvan and FoszczyńskaandKłoda, Małgorzata and KarczmarekandBorowska, Bożenna and Żawrocki, Anton and Kowalczyk, Anna and Biernat, Wojciech and Jassem, Jacek},
article_location = {Albany},
article_number = {1},
doi = {http://dx.doi.org/10.18632/oncotarget.6375},
keywords = {breast cancer; epidermal growth factor receptor type 2; lapatinib; mTOR; p-MAPK},
language = {eng},
issn = {1949-2553},
journal = {Oncotarget},
title = {Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients},
url = {https://www.oncotarget.com/article/22027/text/},
volume = {7},
year = {2016}
}
TY - JOUR
ID - 1369178
AU - Duchnowska, Renata - Wysocki, Piotr J. - Korski, Konstanty - Czartoryska-Arłukowicz, Bogumiła - Niwińska, Anna - Orlikowska, Marlena - Radecka, Barbara - Studziński, Maciej - Demlová, Regina - Ziółkowska, Barbara - Merdalska, Monika - Hajac, Łukasz - Myśliwiec, Paulina - Zuziak, Dorota - Dębska-Szmich, Sylwia - Lang, Istvan - Foszczyńska-Kłoda, Małgorzata - Karczmarek-Borowska, Bożenna - Żawrocki, Anton - Kowalczyk, Anna - Biernat, Wojciech - Jassem, Jacek
PY - 2016
TI - Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients
JF - Oncotarget
VL - 7
IS - 1
SP - 550-564
EP - 550-564
PB - Impact Journals
SN - 19492553
KW - breast cancer
KW - epidermal growth factor receptor type 2
KW - lapatinib
KW - mTOR
KW - p-MAPK
UR - https://www.oncotarget.com/article/22027/text/
L2 - https://www.oncotarget.com/article/22027/text/
N2 - Molecular mechanisms of lapatinib resistance in breast cancer are not well understood. The aim of this study was to correlate expression of selected proteins involved in ErbB family signaling pathways with clinical efficacy of lapatinib. Study group included 270 HER2-positive advanced breast cancer patients treated with lapatinib and capecitabine. Immunohistochemical expression of phosphorylated adenosine monophosphate-activated protein (p-AMPK), mitogen-activated protein kinase (p-MAPK), phospho (p)-p70S6K, cyclin E, phosphatase and tensin homolog were analyzed in primary breast cancer samples. The best discriminative value for progression-free survival (PFS) was established for each biomarker and subjected to multivariate analysis. At least one biomarker was determined in 199 patients. Expression of p-p70S6K was independently associated with longer (HR 0.45; 95% CI: 0.25-0.81; p = 0.009), and cyclin E with shorter PFS (HR 1.83; 95% CI: 1.06-3.14; p = 0.029). Expression of p-MAPK (HR 1.61; 95% CI 1.13-2.29; p = 0.009) and cyclin E (HR 2.99; 95% CI: 1.29-6.94; p = 0.011) was correlated with shorter, and expression of estrogen receptor (HR 0.65; 95% CI 0.43-0.98; p = 0.041) with longer overall survival. Expression of p-AMPK negatively impacted response to treatment (HR 3.31; 95% CI 1.48-7.44; p = 0.004) and disease control (HR 3.07; 95% CI 1.25-7.58; p = 0.015). In conclusion: the efficacy of lapatinib seems to be associated with the activity of downstream signaling pathways - AMPK/mTOR and Ras/Raf/MAPK. Further research is warranted to assess the clinical utility of these data and to determine a potential role of combining lapatinib with MAPK pathway inhibitors.
ER -
DUCHNOWSKA, Renata, Piotr J. WYSOCKI, Konstanty KORSKI, Bogumiła CZARTORYSKA-ARŁUKOWICZ, Anna NIWI$\backslash$'NSKA, Marlena ORLIKOWSKA, Barbara RADECKA, Maciej STUDZI$\backslash$'NSKI, Regina DEMLOVÁ, Barbara ZIÓŁKOWSKA, Monika MERDALSKA, Łukasz HAJAC, Paulina MY$\backslash$'SLIWIEC, Dorota ZUZIAK, Sylwia DĘBSKA-SZMICH, Istvan LANG, Małgorzata FOSZCZY$\backslash$'NSKA-KŁODA, Bo$\backslash$.zenna KARCZMAREK-BOROWSKA, Anton $\backslash$.ZAWROCKI, Anna KOWALCZYK, Wojciech BIERNAT a Jacek JASSEM. Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. \textit{Oncotarget}. Albany: Impact Journals, 2016, roč.~7, č.~1, s.~550-564. ISSN~1949-2553. Dostupné z: https://dx.doi.org/10.18632/oncotarget.6375.
|
